Quantum-Si Incorporated reported second quarter 2026 revenue of $344 thousand, a decline from $591 thousand in the prior year period, driven by the transition from its Platinum platform to the upcoming Proteus system. The company announced a reduction in force affecting approximately 20% of its workforce and updated the anticipated commercial launch timeline for its Proteus instrument to Q2 2027 to improve manufacturing readiness. These cost-reduction actions are expected to generate $12 million in annualized operating expense savings and extend the company's cash runway into Q4 2028, supported by $169.9 million in cash and investments as of June 30, 2026. Quantum-Si operates in the proteomics technology industry, developing single-molecule protein sequencing platforms for research and commercial applications.